HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar

Executive Summary

Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.

You may also be interested in...



P&G ‘Clear-Eyed’ On Challenges Ahead; Growth Will Soften, But Strategic Priorities Go Unchanged

Environmental sustainability and DEI will remain key priorities for P&G as it enters a fiscal 2023 that augurs even greater volatility than 2022. The firm’s net sales for the 12 months ended 30 June increased 5%, or 7% organic, to $80.2bn, propelled by an 8% pricing increase in the fourth quarter.

Chr. Hansen Flags Challenging Outlook For Probiotic Supplements Market

The global probiotic supplements industry is facing a "very challenging time" given the worsening macroeconomic situation, according to Danish ingredients supplier Chr. Hansen.

Consumer Elasticity Exceeds P&G Expectations

With high consumer elasticity not expected to last, P&G adapted to price sensitivity by offering “price levers across brands,” says CFO Andre Schulten  A strong cough/cold season drove 50% organic sales growth in personal health care products in North America.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel